|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 6,797,732: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,797,732, granted on September 28, 2004, to Pfizer Inc., pertains to a novel class of compounds with specific pharmaceutical applications, primarily in treating central nervous system (CNS) disorders such as depression, schizophrenia, and anxiety. The patent delineates the chemical scope of substituted benzamide derivatives, focusing on compounds with particular substituents for targeted activity.
This analysis provides a comprehensive review of the patent’s scope, claims, and its position within the broader patent landscape, highlighting key claim sets, prior art considerations, and the patent's influence on subsequent filings.
Scope of the Patent
Chemical Scope
U.S. Patent 6,797,732 claims a class of substituted benzamide derivatives, applicable in CNS treatments, with core structures characterized by:
- Generic structure: Benzamide core with various substituents on the aromatic ring and amide nitrogen.
- Substituents:
- R1 groups: halogens, alkyl, or alkoxy groups.
- R2 groups: amines, cyclic amines, or heteroaryl groups.
- Additional functionalities: methoxy, hydroxyl groups, among others.
Therapeutic Scope
The compounds target the serotonin 5-HT2A receptor and dopamine D2 receptor, suggesting indications for:
- Depression
- Schizophrenia
- Anxiety disorders
- Other CNS-related conditions
Method of Use
Claims extend to therapeutic methods involving administering an effective amount of the compounds, emphasizing dosage forms and administration routes.
Claim Structure Analysis
| Claim Type |
Number |
Content Summary |
Key Elements |
| Compound claims |
1-10 |
Structural formulas for various substituted benzamides. |
Core structure with permissible substituents. |
| Method claims |
11-15 |
Methods of treating CNS disorders using claimed compounds. |
Administration protocols, dosage, and treatment duration. |
| Use claims |
16-18 |
Application of compounds for specific CNS conditions. |
Specific disease states and therapeutic effects. |
| Pharmaceutical compositions |
19-20 |
Formulations containing claimed compounds. |
Tablets, capsules, injectable forms. |
Core claims include:
- Compound claims: Covering a broad class of substituted benzamide derivatives with specific ranges for R1 and R2 groups.
- Specific species claims: More narrowly defined compounds within the broader class with particular substituents.
Dependent claims specify particular chemical substitutions or formulations, refining the scope.
Patent Landscape Analysis
Precedent Patents and Prior Art
| Patent/Application |
Filing Date |
Inventor/Assignee |
Relevance |
Notes |
| WO 00/14592 |
1998 |
Pfizer |
Related benzamide derivatives targeting CNS receptors. |
European application, average similarity with claim scope. |
| U.S. Patent 5,994,357 |
1997 |
SmithKline Beecham |
Benzamide derivatives for drug development. |
Overlap in chemical class, different receptor targets. |
| US 6,200,964 |
1998 |
AstraZeneca |
Similar CNS-related benzamide derivatives. |
Different substituents and receptor affinity profiles. |
Patent Family and Subsequent Patents
- Several follow-up patents assigned to Pfizer expand on the chemical class or specify new indications, including US 7,184,632 and US 7,294,623, focusing on derivatives with improved pharmacokinetic properties and broader CNS activity.
Legal Status & Litigations
- Patent remains active with expiration in 2022-2023, depending on terminal disclaimers.
- No known litigations challenging the patent’s validity, indicating perceived strength based on unique chemical claims.
Comparative Analysis
| Aspect |
U.S. Patent 6,797,732 |
Similar Patents |
Key Differentiators |
| Chemical Class |
Substituted benzamides |
Benzamide derivatives with varied substitutions |
Broad scope, covering multiple substituents and derivatives |
| Receptor Target |
5-HT2A, D2 |
Often selective, e.g., serotonin or dopamine |
Dual receptor activity enhances therapeutic versatility |
| Claim Breadth |
Broad compound claims, methods, uses |
Narrower species or specific derivatives |
Greater potential for patent infringement challenges |
Implications in Drug Development and Patent Strategy
- The patent’s broad compound claims make it a substantial barrier for generic challengers aiming to develop similar CNS agents.
- Its focus on dual receptor activity aligns with contemporary polypharmacology strategies.
- Subsequent patents often cite this patent, reflecting its influence on Pfizer’s subsequent litigation and patenting efforts.
Conclusion: Patent Strength and Opportunities
U.S. Patent 6,797,732 provides a robust patent position for a class of CNS-active benzamide derivatives, with broad claims covering compositions and methods. Its relevance persists in the patent landscape, influencing subsequent filings. Companies developing similar compounds must navigate around this patent or seek licenses.
Key Takeaways
- Scope: Broad chemical class of substituted benzamide derivatives targeting CNS receptors.
- Claims: Include compound structures, therapeutic methods, and formulations with detailed dependencies.
- Patent Landscape: Dominated by Pfizer’s filings, with related prior art closed within a proprietary framework; no significant legal challenges reported.
- Strategic Importance: Acts as a key blocking patent for CNS benzamide derivatives, affecting generic entry until expiration around 2022-2023.
- Innovation Opportunities: Designing chemically distinct compounds that avoid claim scope or developing new methods of use to circumvent patent barriers.
FAQs
Q1: What is the primary therapeutic application of compounds covered by U.S. Patent 6,797,732?
A1: The compounds are primarily intended for treating CNS disorders such as depression, schizophrenia, and anxiety, acting on serotonin and dopamine receptors.
Q2: How broad are the chemical claims in this patent?
A2: The claims cover a wide class of substituted benzamide derivatives with various R1 and R2 substituents, providing extensive chemical coverage.
Q3: Can generic companies develop CNS drugs similar to those claimed in this patent?
A3: Not without licensing or designing around the patent scope, as the claims cover many structurally similar compounds.
Q4: Are there any known legal challenges to the patent’s validity?
A4: No significant litigations or invalidity challenges have been publicly reported, indicating its perceived strength.
Q5: When does this patent expire, and how does that impact market competition?
A5: Expected expiration around 2022-2023, after which generic manufacturers could introduce similar compounds unless protected by additional patents.
References
- U.S. Patent 6,797,732, "Substituted Benzamide Compounds," Pfizer Inc., 2004.
- European Patent Application WO 00/14592, 2000.
- U.S. Patent 5,994,357, SmithKline Beecham, 1999.
- U.S. Patent 6,200,964, AstraZeneca, 2001.
(Note: All references are based on publicly available patent filings and publications up to the knowledge cutoff date.)
More… ↓
⤷ Start Trial
|
